L-Arginine Supplements in Treating Women Who Are Cancer Survivors

Wake Forest University (WFU)

Status

Completed

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Sexuality and Reproductive Issues

Sexual Dysfunction

Treatments

Dietary Supplement: Placebo

Dietary Supplement: ArginMax

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00459134

U10CA081851 (U.S. NIH Grant/Contract)

IRB00001487

REBACCCWFU 97106 (Other Identifier)

Details and patient eligibility

About

RATIONALE: L-arginine supplements may improve the quality of life and sexual function in women who are cancer survivors.

PURPOSE: This randomized clinical trial is studying an L-arginine supplement to see how well it works compared with a placebo in treating women who are cancer survivors.

Full description

OBJECTIVES:

Primary

Determine whether an L-arginine-based nutritional supplement (ArginMax®) improves the quality of life and sexual function in female cancer survivors.

Secondary

Compare quality of life of patients treated with ArginMax® vs placebo.
Compare toxicity of these regimens in these patients.
Describe the sexual function symptom clusters (if any) in these patients.

OUTLINE: This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. Patients are stratified according to ECOG performance status (0 or 1 vs 2 or 3), type of malignancy (pelvic vs nonpelvic), and ovarian functional status (yes vs no). Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive an oral L-arginine-based nutritional supplement (ArginMax®) twice daily.
Arm II: Patients receive oral placebo twice daily. In both arms, treatment continues for 12 weeks in the absence of unacceptable toxicity.

Sexual function, quality of life, and toxicity are assessed at baseline and every 4 weeks for 12 weeks.

PROJECTED ACCRUAL: A total of 186 patients will be accrued for this study.

Enrollment

186 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Any female cancer survivor who identifies herself as concerned with her sexual quality of life and answering yes to all three of the screening questions.

Must express interest in sexual activity
At least 6 months following completion of all cancer therapy. Hormonal therapy and treatment with Herceptin are allowed.
No evidence of active cancer based on physical exam and/or radiographic images obtained within 3 months of study.
Absence of any mental, medical or physical disorder know to affect sexual function.
No participation in another study with an investigational study drug or device during the 30 days prior to start of study drug.
Lab values must meet the following criteria at study entry: WBC ≥ 2000, Hgb ≥ 10gm/dl, creatinine ≤ 1.5 x ULN, plt ≥ 100,000, T Bili ≤ 1.5
ECOG performance status must be 0-2.
Must be able to take oral medication
Must be 18 years old or older
Must be minority (non-white) female.

Exclusion criteria

History of allergic reactions attributed to compounds of similar chemical or biologic composition to ArginMax.
Currently taking any blood thinner such as aspirin (one 81mg aspirin, or one baby aspirin per day allowed), Persantine, Heparin, Lovenox, or Coumadin (low dose Coumadin for catheter patency is allowed).
Patients currently taking Ginkgo Biloba are not allowed on this study.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac, arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements and/or ability for sexual function.
Pregnant women are excluded from this study because ArginMax may be an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ArginMax, breastfeeding should be discontinued if the mother is treated with ArginMax.
Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with ArginMax. Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.
Any planned surgery during study participation.